Preterm Birth Diagnostic Test Kits Market - By Product Type (Fetal Fibronectin Test Kits, Placental Alpha Micro-Globulin-1 Test Kits, Insulin Like Growth Factor Binding Protein-1 Test Kits), By Sample Type (Blood Sample, Urine Sample, Vaginal Discharge Sample), By End-use, & Forecast to 2032

Preterm Birth Diagnostic Test Kits Market Size

Preterm Birth Diagnostic Test Kits Market size was valued at over USD 419 million in 2022 and is anticipated to grow at a CAGR of over 7.4% between 2023 and 2032. Preterm birth diagnostic test kits are medical devices or tools used to assess the risk of preterm birth in pregnant women. These tests help healthcare providers identify women that are at elevated risk of delivering their babies before 37 weeks of gestation. Additionally, the high incidence of preterm births is accelerating market growth.
 

Moreover, increasing awareness helps pregnant women, families, and healthcare providers recognize the signs and symptoms of preterm labor. Early recognition allows for prompt medical intervention, potentially preventing or managing preterm birth more effectively. Additionally, increased awareness can drive advocacy efforts aimed at improving healthcare policies, funding, and research focused on preterm birth prevention, treatment, and long-term outcomes. It helps foster collaboration among healthcare professionals, policymakers, and community organizations to address the challenges associated with preterm births, thereby augmenting preterm birth diagnostic test kits market growth. In addition, several market players are emphasizing on research and development activities for the development of novel preterm birth diagnostic test kits.

COVID-19 Impact

The COVID-19 epidemic had a moderately negative impact on the preterm birth diagnostic test kits market. The pandemic led to disruptions in healthcare systems globally, with resources and attention primarily focused on managing and responding to COVID-19. This resulted in reduced availability and access to routine preterm birth diagnostic testing. The focus of healthcare systems and researchers was largely on combating COVID-19, leading to a temporary shift in priorities away from other areas, including preterm birth diagnostics. Funding and resources were redirected towards pandemic-related efforts.
 

However, post pandemic to adapt to the challenges posed by the pandemic, healthcare providers have increasingly adopted telemedicine and remote testing options. Such innovations have helped bridge the gap in access to preterm birth diagnostic test kits. Therefore, COVID-19 pandemic hindered the preterm birth diagnostic test kits industry expansion.
 

Preterm Birth Diagnostic Test Kits Market Trends

The rising incidence of preterm births, as well as the improved survival rates of premature infants, has contributed to the need for more neonatal ICUs. Preterm infants often require specialized care due to their unique medical needs and higher vulnerability to complications. Technological advancements in medical equipment, monitoring systems, and treatment modalities have allowed for more complex and specialized care in paediatric and neonatal ICUs. These advancements have driven the establishment of new units to provide the necessary infrastructure and resources. Additionally, paediatric, and neonatal ICUs increasingly prioritize family-centered care, recognizing the importance of involving parents and caregivers in the care of their child. This approach supports parental involvement, communication, and emotional support, creating a more inclusive and supportive environment for families. Thus, such initiatives will lead to high product demand in the near future.
 

Preterm Birth Diagnostic Test Kits Market Analysis

Based on product type, the preterm birth diagnostic test kits market is segmented into fetal fibronectin test kits (fFN), placental alpha micro-globulin-1 test kits (PAMG-1), insulin like growth factor binding protein-1 test kits (IGFBP-1), and others. The fetal fibronectin test kits (fFN) segment held the largest revenue size over USD 197 million in 2022 and is estimated to witness significant growth more than USD 409 million by 2032. The fFN test demonstrates high sensitivity in detecting the presence of fetal fibronectin, a protein that acts as a biomarker for preterm birth. It can accurately identify women at higher risk of delivering prematurely. Furthermore, an increase in the availability of product type coupled with several other businesses working towards creating innovative technology will support the segment's revenue growth in the coming years.
 

Preterm birth diagnostic test kits market is bifurcated based on the sample type including blood sample, urine sample, and vaginal discharge sample. The blood sample segment dominated the market and is anticipated to grow over USD 347 million by 2032. Blood-based tests have demonstrated high diagnostic accuracy in identifying biomarkers and indicators associated with preterm birth. These tests can measure specific proteins, hormones, or genetic markers present in the maternal blood that may be indicative of an increased risk of preterm birth. Thus, the aforementioned factors will drive the segmental growth.
 

The industry is segmented by end-use into hospitals, diagnostic centers, clinics, and others. Diagnostic centers segment dominated the global preterm birth diagnostic test kits market accounting for more than 43% market share in 2022 and is estimated to witness significant revenue over USD 370 million by 2032. The diagnostic centers segment is anticipated to hold high growth potential during the analysis period. Factors such as surging laboratory tests and rising preference towards diagnostics laboratories due to presence of advanced technologies and cost-effective treatment will fuel market growth. Additionally, these centers provide early and accurate disease diagnosis and patient management, thus, anticipated to augment the segmental growth in upcoming years.
 

U.S. preterm birth diagnostic test kits industry accounted for more than USD 158 million in 2022 and will grow momentously more than USD 344 million by 2032. The affordability of preterm birth diagnostic test kits among the target population base and ongoing technological developments are primarily responsible for the growth of the regional preterm birth diagnostic test kits industry. Further, the region's high healthcare spending on health care management and rising disposable income will propel the expansion of the North America preterm birth diagnostic test kits market. Also, the substantial presence of well-established market participants and the favourable regulatory environment result in a number of product approvals and launches, particularly in the U.S. hence, the potential for market expansion will stimulate over the coming years.
 

Preterm Birth Diagnostic Test Kits Market Share

Some of the notable key industry players operating in the preterm birth diagnostic test kits industry include:

• Abbott
• Creative Diagnostics
• Clinical Innovations
• Hologic
• IQ Products
• Qiagen
• Medixbiochemica
• Biosynex
• CooperSurgical Inc
• Sera Progonstics
• Stryker Corporation
   

 These market participants are implementing various growth strategies such as collaborations, partnerships, acquisitions & mergers, and new product development and launches to strengthen product type offerings as well as gain a competitive edge over others.
 

Preterm Birth Diagnostic Test Kits Market News: 

• In June 2021, Medix Biochemica declared the launch of ‘MedixMDx’, a new molecular diagnostic reagents division offering a vast range of products and services. Such initiatives are anticipated to bolster market growth.
   

Preterm birth diagnostic test kits market research report includes an in-depth coverage of the industry with estimates & forecast in terms of revenue in USD from 2018 to 2032 for the following segments:

Click here to Buy Section of this Report

By Product Type

• Fetal fibronectin test kits (fFN)
•  Placental alpha micro-globulin-1 test kits (PAMG-1)
• Insulin like growth factor binding protein-1 test kits (IGFBP-1)
• Others

By Sample Type

• Blood sample
• Urine sample
• Vaginal discharge sample

By End-use

• Hospitals
• Diagnostic centers
• Clinics
• Others

The above information is provided for the following regions and countries:

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • France
  • UK
  • Spain
  • Italy
  • Russia
  • Poland
  • Switzerland
  • Norway
  • Finland
  • Sweden
  • Denmark
  • The Netherlands
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • South Korea
  • Taiwan
  • Indonesia
  • Vietnam
• Latin America
  • Brazil
  • Mexico
  • Argentina
  • Colombia
  • Chile
• Middle East & Africa
  • Saudi Arabia
  • South Africa
  • UAE
  • Israel